Multiple System Atrophy (MSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Multiple System Atrophy (MSA) Marketed and Pipeline Drugs Report Overview
MSA is a rare, sporadic, progressive neurological disorder characterized by various symptoms and signs. There is about one living case of MSA in the population for every 40 cases of Parkinson’s disease (PD). However, survival in MSA is shorter than for PD, with about one new MSA case diagnosed each year for every 20 new PD cases.
The MSA marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for MSA.
The report also provides actionable insights into the clinical and commercial landscapes of AH, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
| Key Mechanisms of Action (Pipeline) | · Protein and Peptide Inhibitors
· Enzyme Inhibitors · Receptor Antagonists · Receptor Modulators |
| Top Sponsors (Marketed and Pipeline Drugs) | · Vanderbilt University Medical Center
· H. Lundbeck AS · Alterity Therapeutics Ltd · AFFiRis AG · Mayo Clinic |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Multiple System Atrophy Pipeline Drugs Segmentation by Mechanisms of Action
Most of the pipeline drugs for MSA are protein and peptide inhibitors in 2024. They are followed by enzyme inhibitors, receptor antagonists, and receptor modulators.
Multiple System Atrophy Pipeline Drugs Analysis by Mechanisms of Action, 2024 (%)
Buy the Full Report to Know More about the MoA of Multiple System Atrophy Pipeline Drugs
Multiple System Atrophy Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the MSA marketed and pipeline drugs market are Vanderbilt University Medical Center, H. Lundbeck AS, Alterity Therapeutics Ltd, AFFiRis AG, Mayo Clinic, and others. Vanderbilt University Medical Center, H. Lundbeck AS, and Alterity Therapeutics Ltd combined are sponsoring the highest number of trials in 2024.
Multiple System Atrophy Marketed and Pipeline Drugs Market Analysis by Sponsors, 2024 (%)
Buy the Full Report for More Sponsor Insights into the Multiple System Atrophy Marketed and Pipeline Drugs Market or Download a Free Report Sample
Segments Covered in the Report
MSA Pipeline Drugs Mechanisms of Action Outlook (2024)
- Protein and Peptide Inhibitors
- Enzyme Inhibitors
- Receptor Antagonists
- Receptor Modulators
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the MSA market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Multiple System Atrophy (MSA) market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for multiple system atrophy marketed drugs in 2024?
Most of the pipeline drugs for MSA are protein and peptide inhibitors in 2024.
-
Which companies are sponsoring the highest number of trials in the multiple system atrophy marketed and pipeline drugs in 2024?
Vanderbilt University Medical Center, H. Lundbeck AS, and Alterity Therapeutics Ltd combined are sponsoring the highest number of trials in 2024 in the multiple system atrophy marketed and pipeline drugs.
-
Which are the top sponsors in the Multiple System Atrophy marketed and pipeline drugs market?
A few of the top sponsors in the multiple system atrophy marketed and pipeline drugs market are Vanderbilt University Medical Center, H. Lundbeck AS, Alterity Therapeutics Ltd, AFFiRis AG, Mayo Clinic, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745

